This company has been marked as potentially delisted and may not be actively trading. Akero Therapeutics (AKRO) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for AKRO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Akero Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKRO Analyst Ratings Over TimeTypeCurrent Forecast5/22/25 to 5/22/261 Month Ago4/22/25 to 4/22/263 Months Ago2/21/25 to 2/21/261 Year Ago5/22/24 to 5/22/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)3 Buy rating(s)4 Buy rating(s)8 Buy rating(s)Hold7 Hold rating(s)7 Hold rating(s)7 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$60.80$63.67$63.67$82.33Forecasted Upside11.25% Upside16.50% Upside16.50% Upside68.13% UpsideConsensus RatingHoldHoldHoldBuy AKRO Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History AKRO Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Akero Therapeutics Stock vs. The CompetitionTypeAkero TherapeuticsMedical CompaniesBroader MarketConsensus Rating Score 2.10 2.29 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside11.25% Upside1,714.69% Upside15.95% UpsideNews Sentiment RatingNeutral NewsSee Recent AKRO NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails12/10/2025 Cantor Fitzgerald5 of 5 starsPrakhar AgrawalNot RatedReiterated RatingOverweight10/10/2025 HC Wainwright4 of 5 starsAndrew Fein5 of 5 starsReiterated RatingBuy ➝ Neutral$72.00 ➝ $54.00-0.15%10/10/2025 Zacks ResearchNot Rated DowngradeStrong-Buy ➝ Hold10/10/2025 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRitu BaralSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndy ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Hold10/9/2025 Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold10/9/2025 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrew TsaiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $56.00+3.35%10/9/2025 Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEdward NashSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$73.00 ➝ $54.00-0.43%10/8/2025 Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingSell (D-)5/27/2025 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAlexandria HammondSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$63.00 ➝ $64.00+30.29% Get the Latest News and Ratings for AKRO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/13/2025 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJ. WooSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$80.00 ➝ $78.00+89.55%3/2/2025 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOverweight1/31/2025 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEliana MerleSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$42.00 ➝ $109.00+104.01%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:29 AM ET. AKRO Forecast - Frequently Asked Questions What is Akero Therapeutics' forecast for 2026? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Akero Therapeutics is $60.80, with a high forecast of $76.00 and a low forecast of $54.00. Should I buy or sell Akero Therapeutics stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last twelve months. There is currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AKRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKRO, but not buy additional shares or sell existing shares. Does Akero Therapeutics's stock price have much upside? According to analysts, Akero Therapeutics's stock has a predicted upside of 11.25% based on their 12-month stock forecasts. Do Wall Street analysts like Akero Therapeutics more than its competitors? Analysts like Akero Therapeutics less than other "medical" companies. The consensus rating score for Akero Therapeutics is 2.10 while the average consensus rating score for "medical" companies is 2.29. Learn more on how AKRO compares to other companies. Stock Forecasts and Research Tools Related Companies GMAB Stock Forecast ASND Stock Forecast SMMT Stock Forecast RGC Stock Forecast BBIO Stock Forecast AXSM Stock Forecast ARWR Stock Forecast ELAN Stock Forecast RDY Stock Forecast ABVX Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Akero Therapeutics RecommendationsCantor FitzgeraldWall Street ZenTD CowenHC WainwrightZacks ResearchWolfe ResearchLifesci CapitalJefferies Financial GroupCanaccord Genuity GroupWeiss RatingsBank of America This page (NASDAQ:AKRO) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
